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Abstract The small airways constitute one of the least understood areas of the lungs.They play a role in many lung
diseases, and small airway pathology results in signi¢cant morbidity.New approaches to their evaluation may provide
insights into thismajor area of lung disease. Asthma iswell recognized as a disease of both large and small airways. Phy-
siological and pathological evidence, from techniques such as post-mortem tissue histological analysis, induced sputum
and transbronchial biopsies, has reinforced the concept of the involvement of the entire bronchial tree in the in£amma-
toryprocessin asthma.In additionto describing the airwaypathologyin asthma, thisreview focuses onthepathogenesis
and role of small airway obstruction in other diseases, including chronic obstructive pulmonary disease (COPD), idio-
pathic pulmonary ¢brosis (IPF), sarcoidosis and obliterative bronchiolitis (OB).COPD is characterized by the presence
of air£owobstruction resulting fromlesions in the small airways. In addition, features compatiblewith small airways dis-
ease are common in IPF, sarcoidosis and OB.Recent advances in pulmonary imaging, such as high-resolution computed
tomography (HRCT) andmagneticresonanceimaging (MRI)withhyperpolarized 3He, have allowednon-invasiverepro-
duciblemeasurements of structure^functionrelationships tobemade for the small airways.Thesetechniqueshavegreat
potential for diagnosing changes in small airway function and for assessing responses to treatment.Newinsights into the
contribution of small airways to a range of lungdiseasesmaylead tothe developmentoftherapies targeted atthis partof
the bronchial anatomy.r2001Elsevier Science Ltd
doi:10.1053/rmed.2001.1216, available online athttp://www.idealibrary.comon
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ASTHMA
Asthma is a common disease, a¡ecting 5^10% of adults.
Recent evidence has shown that asthma is a disease that
a¡ects both the large and small airways (1).The small air-
ways (r2mminternalperimeter) o¡er lowresistance to
air£ow and normally contribute only around 10% of the
total resistance. As such, they have been termed the ‘si-
lent zone’ (2). However, due to the di⁄culty of in vivo
sampling and lack of respiratory function tests speci¢cReceived 30November 2000, accepted in revised form 24 August 2001
and published online10 December 2001.
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Fax: 020 8383 3361; E-mail: r.shaw@ic.ac.ukto this site, small airway obstruction has been largely un-
der-evaluated (3^5). Evidence demonstrating that in-
£ammatory and structural changes, including ¢broblast
proliferation and collagen deposition, occur throughout
the airways in asthma has recently been reviewed (5^9).
In£ammatory and structural changes
A study undertaken to examine airway dimensions in
fatal and non-fatal asthma has demonstrated that both
the large and small airways exhibit a signi¢cantly greater
(Po0?05) cross-sectional total wall area in patients with
fatal asthmawhen comparedwith control cases (10).The
data indicate that swelling and in£ammation occur in
both the large and small airways.
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nature and involves mast cells, eosinophils, neutrophils
and T-lymphocytes, and their in£ammatory mediators
such as cytokines and chemokines (6).Mesenchymal cells
such as epithelial cells, ¢broblasts, smooth muscle cells
and endothelial cells also participate in the in£ammatory
response (5,7,8). A recent investigation has suggested
that in¢ltration of the bronchial mucosa by eosinophils
is a feature of both large and small airways, with a greater
intensity in the proximal airways in acute severe asthma
(11). Hamid et al. (1) showed that there is a similar but
more severe in£ammatory process present in the peri-
pheral compared with central airways of patients with
non-fatal asthma, which is consistent with the fact that
the smaller airways are a major site of obstruction in
asthma. Analysis of resected lung tissue from asthmatic
subjects has also revealed that T cell and eosinophil accu-
mulation was present in both large and small airways,
with increased numbers of activated eosinophils present
within the small airways when compared with the large
airways. Histological examination of autopsy material
has identi¢ed mucous plugging in small airways which
are devoid of mucus-secreting glands (12). The data sug-
gest that small airways may be in part responsible for
the gas exchange abnormalities observed in asthma.
Other structural changes include patchy epithelial da-
mage with loss of the columnar ciliated epithelial cells,
revealing an epithelium decreased down to the basal
epithelial cell layer andevidence of airway wall thickening
(13,14). Airway wall ¢brosis and increased collagen ¢bril
formation within the submucosal matrix, as well as
smooth muscle hypertrophy and hyperplasia and en-
hanced vascularity, are some of the causes of airwaywall
thickening (15^17). Increased expression of pro-¢bro-
genic factors, including endothelin, ¢broblast growth
factor II and transforming factor-b, have been observed
within the airways in asthma (7). These growth factors
have a number of cellular sources but epithelial cell, eosi-
nophil and macrophage activation will contribute to the
release of these products, thus linking airway in£amma-
tion with airway structural changes. A relation between
small airways abnormalities and speci¢cmeasures of lung
function has been demonstrated, with increases in dis-
ease in small airways correlating with deterioration in
lung function (18).
In summary, all cells of the airways can actively
participate in thepathogenesis of bronchial in£ammation
in asthma (5). Both in£ammatory and mesenchymal
cells are in an activated state and create a complex
cellular network which modulates the in£ammatory
changes. These changes can lead to the development
of airway remodelling which may, in turn, cause perma-
nent narrowing of the lumen in both the large and small
airways.
The data derived from all these studies have provid-





Chronic obstructive pulmonary disease (COPD) is a se-
vere chronic respiratory condition characterizedby pro-
gressive, irreversible air£ow limitation. The worldwide
incidence of COPD is increasing and, as a result, so is
the social and economic burden (19). In most pa-
tients, COPD is the result of long-term heavy cigarette
smoking, even though approximately10%ofpatientswith
COPD are non-smokers (20).Other environmental fac-
tors such as pollutants, passive smoking or other inhaled
toxinsmay be involved (20).
In£ammatory and structural changes
InpatientswithCOPD, avarietyof structural changes take
place, including acute and chronic in£ammatory in¢ltrates
in thewalls of the large and small airways, enlargement of
the bronchial mucus glands, increased intraluminalmucus,
¢brosis and distortions in the shape of airways (21).
Hogg et al. (22) showed that disease in the small air-
ways, not the central bronchi, is mainly responsible for
the increased pulmonary resistance observed in COPD.
Since the pathology responsible for this increased per-
ipheral resistance was thought to comprise a variety of
lesions, not all in£ammatory, they introduced the term
‘small airways disease’. Pathological changes in the small
airways have been described in detail (23^25). Many
non-cartilaginous bronchioles have thickened walls and
are in£amed, smooth muscle is hypertrophied and focal
areas of mucosa are ulcerated.The bronchiolar lumen is
deformed, resulting from alternating regions of stenosis
and dilation (23).
The in£ammatory changes in COPD consist mainly of
lymphocyte and plasma cell in¢ltration. Bronchoalveolar
lavage (BAL) and induced sputum in patients with COPD
demonstrate increased numbers of neutrophils and
macrophages (26). At sites of lung destruction in the lung
parenchyma there are increased numbers of macro-
phages and CD8+ T-lymphocytes, and similar changes
are seen in the airway walls (27).
In summary,COPDis characterizedby thepresence of
air£ow obstruction resulting from various small airway
lesions. Small airways of COPD patients are characte-
rized by features such as mucous gland hypertrophy,
airway narrowing and increased intra-luminal mucus. In
addition to these structural changes, in£ammatory pro-
cesses also take place.
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Interstitial lung diseases (also termed ‘di¡use parenchy-
mal lung diseases’) comprise a group of pulmonary
disorders which are individually relatively uncommon
but collectively have a prevalence of around 50per
100 000 population (28). They may be associated with
several risk factors such as environmental exposure, ge-
netic predisposition, gender, age and race. These disor-
ders cause major morbidity and mortality due to lung
injury and ¢brosis. They are characterized clinically by
di¡use in¢ltrates seen on the chest radiograph, altered
pulmonary histology, restrictive lung function, reduced
gas transfer and impaired oxygenation re£ected in a
variety of pulmonary function tests, depending on the
extent and severity of the disease. The pathogenesis of
interstitial lung diseases primarily involves the small air-
ways and alveoli (29,30). The typical physiological ab-
normality is lung restriction and impaired gas transfer
due to ¢brosis and in£ammatory in¢ltrates.Maximal ex-
piratory £ow rates are well preserved due to the in-
creased elastic recoil pressure of the poorly compliant
tissue. This results in a normal or increased forced ex-
piratory volume in1sec/forced vital capacity (FEV1/FVC)
ratio (31).
The diagnosis of a speci¢c interstitial lung disease is
made by various means including the patient’s history,
speci¢c serologies, BAL, transbronchial biopsy or thora-
coscopic or open lung biopsy. Diagnosis has become ea-
sier with the application of newer and more sensitive
assessment methods such as high-resolution computed
tomography (HRCT), which detects early structural al-
terations in alveolar tissue components. These applica-
tions may allow di¡erences to be distinguished between
disease processes (32).
The disease categorieswithin this group include pneu-
moconiosis, drug-induced pulmonary injury, idiopathic
pulmonary ¢brosis (IPF), non-speci¢c interstitial pneu-
monitis (NSIP), sarcoidosis, hypersensitivity pneumoni-
tis, histiocytosis X and collagen vascular disease. This
review focuses on the pathogenesis and the role of small
airways obstruction in IPF and sarcoidosis.
Idiopathic pulmonary ¢brosis
IPF is themost common type of interstitial lung disease,
accounting for 25^30% of cases (33). In Europe it is also
called ‘cryptogenic ¢brosing alveolitis’. IPF is considered
as a pulmonary disease of unde¢ned aetiology with a
5-year mortality of 50% (34). A recent study has indi-
cated that in newly diagnosed cases of IPF, median survi-
val may be as low as 2?9 years and expected life span is
reducedby approximately 7 years (35).The abnormalities
seen in IPF are typical of interstitial lung diseases in gen-
eral and include ventilatory restriction, di¡usion impair-
ment and gas exchange abnormality.The pathology of IPF involves the alveolar septa
and small airways and is characterized by parenchymal
in£ammation, termedalveolitis, ¢broblastic proliferation
and progressive interstitial ¢brosis (35^37). Fibrosis
of the lung parenchyma is parallelled by in¢ltration
of the lung by in£ammatory and immune e¡ector cells
(36) and by activation and proliferation of ¢broblasts.
Local in£ammation is characterized by the presence
of polymorphonuclear neutrophils and macrophages
(38). These in£ammatory cells release cytokines in re-
sponse to injury, which are principal mediators of ¢bro-
genesis; theydamage the alveolar walls leading initially to
a ¢brin exudate and subsequently to ¢broblastic
in¢ltration. Collagen synthesis by ¢broblasts results in
structural changes and eventually alveolar shrinkage
(39). Cytokines which play a key role in tissue repair
and ¢brosis include transforming growth factor-b
(TGFb), tumour necrosis factor-a (TNFa) and
platelet-derived growth factors (36).TNFa exerts an in-
directrolebyeliciting therelease of other pro-in£amma-
tory cytokines from human alveolar macrophages and
neutrophils.
There is wide histological variability within the lungs
of individual patients depending on the extent and sever-
ity of foci of lung injury, ¢brogenesis and ¢brosis. The
greater the variability, the better the response to ther-
apy, with severe ¢brosis being resistant to treatment
andmild ¢brosismore responsive (40).
Sarcoidosis
Pulmonary sarcoidosis is a chronic granulomatous
disease of unknown aetiology. Features compatible
with small airways disease detected by computed tomo-
graphy (CT) are common in sarcoidosis (41). The
major CT ¢ndings which serve as diagnostic landmarks
in pulmonary sarcoidosis are thickened bronchovascular
bundles, which correspond histologically to granulomas
formed in the connective tissue sheath around the
pulmonary vessels and airways, and bihilar and mediast-
inal lymphadenopathy. It is well established that this dis-
ease is characterized by accumulation of large numbers
of T-lymphocytes and cells of the mononuclear phago-
cyte series, such as alveolar macrophages, at sites of in-
£ammation (42). It is possible that peripheral airway
obstruction with the involvement of small airways is
caused by the formation of granulomas typically seen in
transbronchial biopsies with resultant peri-bronchiolar
¢brosis.
Small airways and obliterative bronchiolitis
Constrictive or obliterative bronchiolitis (OB) refers to
in£ammation and ¢brosis occurring predominantly in
the bronchioles, with few changes in the distal parenchy-
70 RESPIRATORYMEDICINEma, and leading to narrowing of their lumens (43). A
broad spectrum of histological features exists in OB,
from subtle abnormalities to complete luminal oblitera-
tion (44).The primary histological hallmark of OB is the
presence of submucosal bronchiolar ¢brosis.The ¢brotic
process is preceded by bronchiolar in£ammation, which
results in epithelial necrosis. The clinical features of OB
can be divided into three stages: cough, chest pain and
respiratory distress are the symptoms in the ¢rst stage,
whichmay have a duration of up to 2 weeks.This stage is
usually followed by clinical improvement of up to 2
months, and subsequently by cough, progressive dys-
pnoea, expectoration and cyanosis, and may result in
deathwithin1^2 months.
HRCT imaging analysis has provided evidence for the
involvement of small airways in the pathogenesis of OB.
Hansel1 et al. (45) have shown that in patients with OB
the extent of decreased attenuation seen on thoracic
CTwas very strongly related to the degree of abnormal-
ity in tests of small airways function. Physiological
changes inOB include a decrease in FEV1,FEV1/FVCratio,
FVC and the di¡using capacity of the lungs for carbon
monoxide (46).
The pathogenesis of OB may be associated with a
number of other diseases. In rare cases OB may follow
acute bronchiolitis in children due to viral infection.
However, it is more frequently associated with certain
connective tissue and autoimmune diseases, particularly
rheumatoid arthritis.OBmay also occur after inhalation
of toxic gases, such as nitrogen dioxide released during
combustion, or after digestion of certain drugs, such as
penicillamine (43).
Obliterative bronchiolitis following lung
transplantation
The pathogenesis of OB following organ trans-
plantation is multi-factorial. Most cases (up to 60%)
of OB are caused by allograft rejection following lung
or heart^lung transplantation (47). Other underlying
risk factors for the development of OB include
pulmonary infections, such as cytomegalovirus infection,
connective tissue disease and inhalational injury,
including aspiration. OB occurs in 50^60% of lung or
heart^lung recipients by 5 years post-transplantation
(48). In fact, this disease is themost signi¢cant long-term
cause ofmorbidity andmortality following heart or lung
transplantation. Gri⁄th et al. (49) have shown that
the presence of a positive primed lymphocyte test in
the BAL followingheartor lung transplantation indicates
lymphocytic bronchiolitis, a precursor of OB. Further
evidence that OB is an immunologically mediated
phenomenon has since been obtained, indicating
the involvement of T-lymphocytes mainly of cytotoxic
and suppressor phenotype (50,51). The mechanismsunderlying the progression of lymphocytic bronchiolitis
toOB are unknown and are currently under intensive in-
vestigation. However, the interaction of epithelial cells
and mesenchyme is considered important and it is
known that development of OB is heralded by an in-
crease in neutrophils and IL-8 levels in BAL (52). Exhaled
nitric oxide (NO) levels are increased in lung transplant
recipients and their measurements may have a role as a
marker of pulmonary allograft dysfunction (53). Addi-
tionally, morphological surveillance by transbronchial
biopsy has been shown to be a reasonably safe and reli-
able method for the diagnosis of rejection and infection
in lung transplantation (54).
MEASUREMENTOFAIRWAY
INFLAMMATION
The measurement of airway in£ammation plays an im-
portant role in the understanding of the mechanisms of
airway diseases. In addition to conventional non-invasive
techniques, newer techniques, such as HRCT and mag-
netic resonance imaging (MRI) with hyperpolarized 3He,
have advanced our ability to assess abnormalities in per-
ipheral airways and their response to treatment tar-
geted at the lung periphery.
Bronchoalveolar lavage
BAL is used mainly to sample the alveolar region. It is
performed by sequentially instilling and aspirating ali-
quots of isotonic saline to themiddle lobe.The compari-
son of the ¢rst portion, called bronchial wash, with
subsequent BAL £uid, has demonstrated a gradient in
cellular composition with more neutrophils and fewer
macrophages in the peripheral airways compared with
alveoli (55).
Induced sputum
It is nowpossible tomeasure an arrayof indices of airway
in£ammation believed to be relevant to asthma patho-
genesis relatively non-invasively and reliably, using spu-
tum induction by hyperosmolar saline (56,57). Sputum is
induced by inhalation of an aerosol of hyperosmolar sal-
ine, the aerosol being generated by an ultrasonic nebuli-
zer. This method enables sampling of the lower
respiratory tract in patients with asthma and, indeed,
other chronic in£ammatory diseases of the lung, such as
COPD and interstitial lung disease (58,59).
Once the sputum has been homogenized, cells can be
counted using tinctorial methods, immunohistochemis-
try or £ow cytometry. Mediators such as eosinophil ca-
tionic protein (ECP) (60), histamine, tryptase, markers
ofmucous secretion (61) andneutrophil-derivedmarkers
(62) can bemeasured in the supernatants.
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tion, based on increases in speci¢c cells, and the di¡erent
causes of this in£ammation havebeen highlightedby spu-
tum examination (56). It has been reported that, compa-
tible with a central role for eosinophils and mast cells in
asthma, the sputum of asthmatic subjects contains in-
creased numbers of eosinophils and levels of ECP and
mast cell tryptase (63). Cytometric analysis of sputum
lymphocytes in asthma has shown an increase in CD4+
T cells and T cells expressing intracellular adhesionmole-
cule-l as well as a decrease in CD16+ natural killer cells
(63). Amorerecent investigationhas establishedan asso-
ciation between eosinophilic and neutrophilic in£amma-
tion of the airways and disease severity (64), as assessed
by lung function tests such as FEV1 and peak expiratory
£ow (PEF).
The method of sputum examination has been modi-
¢ed tomake it safe for use in patientswith severe air£ow
limitation, such as those with COPD (65). Sputum is in-
duced by inhalation of an aerosol of normal saline fol-
lowed by hypertonic saline and using shorter periods of
inhalation.
Thepresentconsensus on the diagnosis and treatment
of asthma relies on symptoms and lung function mea-
surements for the monitoring of disease severity. Reli-
able measurement of induced sputum cell counts may
have an application in monitoring the anti-in£ammatory
e¡ects of anti-asthma drug therapy (66). The functional
e¡ects of the corticosteroids beclomethasone (67,68),
budesonide (69^71), £uticasone propionate (72) and pre-
dnisolone (73) on airway in£ammation in patients with
asthma have been studied using induced sputum cell
counts alone or in combination with lung function mea-
surements or other in£ammatory indices (e.g. spirome-
try, bronchial responsiveness to constrictor agonists and
exhaledNO).The inability of some of the currently avail-
able inhaled and oral corticosteroids to control fully the
in£ammatory process emphasizes the need for further
research into the dose-dependency of corticosteroid ef-
fects and in£ammatory mechanisms which are poorly
responsive to corticosteroids as targets for new anti-
asthma drugs (63).
A direct comparison of induced sputum, BAL and
bronchial wash showed that they re£ect di¡erent sites
of airway sampling (74). There was increased recovery
of eosinophils and neutrophils in sputum when compar-
ing BALwith bronchialwash.The increasewas re£ected
by a reduction in the percentage of macrophages and
lymphocytes. In BAL there was a larger percentage of
lymphocytes and macrophages in comparison to the
other two sampling techniques. Therefore, it is likely
that the sputum obtained during an induction is derived
mainly from central airways (74). However, the cellular
composition of sputum changes when sputum samples
are produced during three consecutive inhalation peri-
ods (75).The highest percentage of neutrophils occurredin the ¢rst sputum sample, while the lowest proportion
occurred in the sputum that was produced during the
third induction period. At the same time, the percentage
of macrophages increased, indicating that the sputum
originated frommore peripheral airways (75).Therefore
with consecutive sampling, sputum can be used to sam-
ple the small airways andmonitor airway in£ammation.
In summary, these observations highlight the impor-
tance of airway in£ammation in causing asthma and
other small airways diseases. In addition, they con¢rm
the usefulness of sputum induction in assessing features
of the in£ammatory process in the lower respiratory
tract, as well as in understanding the actions of steroids
in the treatment of this disease. This technique may
therefore beuseful to guide treatment in clinical practice
and lead to the development of more e¡ective and safer
drugs for asthma.
Transbronchial biopsies
Biopsies can be taken at di¡erent depths of the airways,
from bronchial mucosal biopsies of the large airway to
transbronchial biopsies of the small airways and lung par-
enchyma.Transbronchial biopsies have been used to de-
monstrate disease and in£ammation in the small
airways (76^79).
Investigation of pulmonary physiology in
nocturnal asthma provides a model for relating
changes in physiology and in£ammation in a naturally oc-
curring situation. A combination of factors may set in
motion the asthmatic response at night, including in-
crease in lower and peripheral airway resistance as
well as in bronchial hyper-reactivity and lung volume
changes (76).
The degree of airway and alveolar in£ammation
has recently been evaluated in nocturnal asthma by
obtaining and analysing airway endobronchial and distal
alveolar tissue trans-bronchial biopsies collected
at bronchoscopy in a random order at 16?00hours and
at 04?00 hours (77). The results indicated that the
numbers of eosinophils and macrophages were signi¢-
cantly greater in the nocturnal asthma alveolar tissue at
04?00 hours compared with 16?00 hours.The overnight
decrease in lung function correlated with the number of
alveolar tissue eosinophils but not with proximal bron-
chial tissue eosinophils.Theseresults suggest that in noc-
turnal asthma there is a greater accumulation of
eosinophils and macrophages in the alveolar tissue, and
that these in£ammatory changes contribute more to
the impairment in lung function, compared with proxi-
mal tissue.
A more recent investigation has demonstrated
that there is a greater number of CD4+ lymphocytes in
the alveolar tissue at night in nocturnal asthma
comparedwith non-nocturnal asthma (78). Additionally,
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phocytes and EG2+ eosinophils in the distal when com-
paredwith proximal airway in nocturnal asthma at both
16?00 hours and 04?00 hours (78). Alveolar (but not
proximal airway) tissue CD4+ cells were found to corre-
late with the nocturnal decrement in lung function and
with the number of alveolar tissue EG2+ cells. The data
fromboth these studies, as well as the studyof Carrollet
al. suggest that in£ammation in the pulmonary parench-
yma area of the lung may play an important role in the
pathogenesis of asthma (79). Excised lung specimens
from cases of asthma showed that in£ammation was si-
milar in magnitude in the large and small airways (79).
Ultrathin bronchoscopy
The introduction of ultrathin bronchoscopes which can
advance further down the airways may provide new in-
formation on airways in asthma.This method allows in-
spection of the peripheral bronchioles to the13th order
branches, revealing the colour of the bronchial mucosa,
morphological changes and existence of secretions and
obstruction.
An ultrathin bronchoscope was used to examine the
peripheral airways of subjects with chronic bronchitis,
pulmonary emphysema and healthy subjects for changes
in the bronchial walls and for endobronchial abnormal-
ities (80). In patients with chronic bronchitis, granular
changes along with either secretions in the peripheral
airways or obstruction at the 11th or 12th generation
bronchialbrancheswere observed. Inpulmonary emphy-
sema, the peripheral airways frequently showed a net-
like appearance of the bronchial epithelium and obstruc-
tion at the11th or12th generation.
Another study using an ultrathin bronchoscope investi-
gated the in£ammatory responses of small airway epithe-
lium in smokers (81). Living epithelial cells were harvested
bybrushing the smallairwaymucusunderdirectvisionwith
anultrathinbronchoscope. A close linkwashighlightedbe-
tween smoking and the expression of in£ammatorymedia-




Reversible expiratory air£ow obstruction can be mea-
sured by tests such as PEF, FEV1, the ratio of FEV1 to
FVC, residual volume and total lung capacity (82,83),
although PEF and FEV1measurements preferentially re-
£ect changes in the central airways. PEF and FEV1 are
now almost always used as themeasures of lung function
as they have been demonstrated to have greater repro-
ducibility than othermeasures (84).Lung function testshave demonstrated that in£amma-
tion and ¢brosis of small airways are related to the
impairment of lung function. Increase in disease in
small airways correlated with deterioration in lung
function (18).
Spirometry has been used to try to identify high-risk
subjects in a group of smokers and ex-smokers followed
for13 years (85). Smokerswere found to be at no evident
risk of rapid functional deterioration if their initial FEV1
vital capacity (VC) ratio was within normal limits. How-
ever, smokers with an initially low FEV1/VC ratio and a
high nitrogen slope of the alveolar plateauwere at higher
riskof developing COPD (85).FEV1/VCratio and lung vo-
lumes [VC and residual volume (RV)] were measured to
small airways obstruction in a group of patients with
asthma, emphysema and small airways disease. Small air-
ways obstruction syndrome was characterized by a de-
creased VC and FEV1 and an increased RV, even when
FEV1/VCwas normal (86).
Changes in small airways function can bemeasuredby
forced expiratory £owover themiddle half of the forced
expiratory curve (FEF25^75%), forced expiratory volume
at 3 sec (FEV3) and measures derived from the single-
breath nitrogen test.
Closing volume and density-dependence of £owmea-
sures such as DVmax50 are more speci¢c indicators of
small airways abnormality, and the latter have been used
to distinguish changes in small and large airway function
in response to therapy withbronchodilators (87). Unfor-
tunately, however, most of these physiological measure-
ments are not always related to symptoms, and due to
their high variability their clinical usefulness is limited
(88,89).
In summary, conventional pulmonary function mea-
surements have contributed to our understanding of
the structure ^function relationships in both physiologi-
cal andpathophysiological conditions.However, it is di⁄-
cult to assess changes in the function of small airways as
some of these measurements may be rather insensitive
and variable and cannot localize the regional heteroge-
neity of bronchial reactivity or expiratory air£ow ob-
struction. These ¢ndings highlight the need for the
development of new objective and reproducible mea-
sures to assess regional variations and to phenotypically
describe changes in peripheral airways function in the
normal and diseased lung.
High-resolution computed tomography
HRCT is a non-invasive imaging technique that can be
used to assess pulmonary structure^ function relation-
ships by measuring the dimensions of individual airways
(32,90,91). Advances in HRCT imaging methodology
and post-imaging data processing tools have allowed di-
rect radiographic evaluation of luminal calibre and wall
FIG. 1. HRCT images (a) and computer-generated LACs (b) demonstrating right upper-lobematched pairs before and aftermetha-
choline challenge at visits 2 (pre-treatment baseline visit) and 4 (post-treatment visit) in a chloro£uorocarbonbeclomethasonedipro-
prionate (CFC-BDP)-treated patient. At both visits 2 and 4, the LAC is similarly shifted to the left after methacholine, indicating the
same degree of increased air trappingduetoregionalhyperresponsiveness tomethacholineboth atbaseline and after treatmentwith
CFC-BDP. (b) RVPre-treament (F) and RV post-treatment (F) HU=Houns¢eldunit.Reproducedwiththepermissionof J.G.Goldin
and Mosby,Inc. (94).
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74 RESPIRATORYMEDICINEthickness of airways 42mm in diameter (92). Direct
measurement of changes in the small airways calibre is
not yet possible due to the limitations of the HRCT ima-
ging technique.However,HRCT canbeused to assess in-
directly the small airways by evaluating regional air
trapping that results from small airways narrowing and
hyperreactivity of the small airways to methacholine
(Figs 1 and 2) (93,94). HRCT has been shown to provide
an accurate and reproducible assessment of small air-
ways inmild asthma and to bemore sensitive than spiro-
metry (93^95). Regional air trapping can be assessed by
analysis of lung attenuation curves (LAC), which repre-
sent the distribution of lung attenuation units within ax-
ial sections in a region of interest. A shift to the left (to
lower attenuation) in the LAC at a given standardized
lung volume (usuallyresidualvolume) re£ects an increase
in air trapping, whereas a shift to the right (to higher at-
tenuation) re£ects improvement in air trapping thatmay
be attributed to therapeutic e⁄cacy (93,94).From analy-
sis of LACs, HRCT can quantify changes in the internal
luminal diameter of peripheral asthmatic airways pro-
voked by bronchoprovocationwithmethacholine inhala-
tion, even in the absence of changes in global pulmonary
function (93,94,96).
Thin-section CT
As an adjunct toHRCT, thin-sectionCT hasbeenused to
evaluate the pathologic phases of airway damage (97). It
can be used to target areas of interest and help detect
otherwise overlooked slight pathological ¢ndings.
Thus, functional HRCT provides reproducible mea-
surements of cross-sectional area of macroscopic air-
ways, as well as regional attenuation characteristics
re£ecting thepatencyofperipheral airways.This imaging
technique is thought to be more sensitive than pulmon-
ary function tests in the early stages of lung damage and
has great potential for use in the diagnosis and longitudi-
nal evaluation of patients with airway diseases.
Magnetic resonance imaging with
hyperpolarized 3He gas
One of the newer andmore sensitive techniques used to
image airspaces of the lung isMRI, using inhaledhyperpo-
larized 3He (98^101).He is usedbecause it can be inhaled
in relatively large quantities without substantial risk as it
is not absorbedby the tissues of the lung (98).Thehyper-
polarized 3He is administered as an inhalative ‘contrast
agent’ allowing for imaging of the airways and airspaces.
Normal ventilation is re£ected by an almost complete
and homogeneous distribution of the hyperpolarized
gas represented by the signal detected. Loss of signal or
inhomogeneous signal distribution represents mass ef-
fects and ventilatory abnormalities.The lung parenchyma of healthy volunteers with nor-
mal lung function showedhomogeneous intermediate to
high signal, whereas patientswith COPDpresentedwith
severe signal inhomogeneities with patchy or wedge-
shaped defects (99). Subjects with seasonal allergies
without pulmonary symptoms have been observed to
exhibit transient ventilation defects (100).
MRI with hyperpolarized 3He is a sensitive tool to de-
tect pulmonary ventilation and its abnormalities. Since
MRI with hyperpolarized 3He has the potential to show
the acinar units of the lungs, it is likely that this technique




As evidence has accumulated that in£ammatory and
structural changes occur throughout the airways, it is
clear that anti-in£ammatory treatment needs to be di-
rectedatboth the large and small airways to achieve sup-
pression of in£ammation throughout the entire
bronchial tree (7). Delivery of drugs to small airways
provides a challenge, since conventional therapy treats
predominantly large airways (102).
As prophylactic agents, corticosteroids have been the
cornerstone of asthma treatment.They suppress in£am-
mation in asthmatic airways and can inhibitmany key as-
pects of the in£ammatory process in asthma (103).
Systemic corticosteroids are often used as short-term
therapy to achieve control of a patient’s asthma or to
speed recovery from a severe attack. Despite the suc-
cess of systemic corticosteroids, long-term use carries
the risk of adverse side e¡ects, and so inhaled corticos-
teroids (ICS) are preferred for long-term therapy.There-
fore, oral corticosteroids have been reserved for acute
exacerbations and severe, chronic disease (104,105). ICS
have now become established as ¢rst-line treatment for
patients with persistent asthma, starting with mild dis-
ease requiring daily use of bronchodilators. ICS have
been shown to control asthma symptoms in patients of
all ages with asthma of all severities. They improve lung
function and prevent disease exacerbations. Moreover,
they are amongst the most cost-e¡ective treatments
currently available for long-term asthma control, as they
reduce the frequency of asthma attacks and so save on
total costs (106).However, even with optimal technique,
only approximately l0^20% of the steroid dose gener-
ated by chloro£uorocarbon (CFC)-based metered-dose
inhalers reaches the lower respiratory tract, with most
of the medication delivered to the lung being deposited
in the large airways (107).
The treatmentofCOPDis symptomatic,withnodrugs
currently available to halt the progression of air£ow ob-
struction. Bronchodilators are the basis of symptomatic
FIG. 2. HRCT images (a) and computer-generated LACs (b) demonstrating rightupper-lobematchedpairs before and aftermetha-
choline challenge at visit 2 (pre-treatment baseline visit) and visit 4 (post-treatment visit) in a hydro£uoroalkane beclomethasone di-
proprionate (HFA-BDP)-treatedpatient.Thereis a decreaseinprominence of lowattenuation, andtherefore air trapping, onthepost-
treatmentcomparedwiththepre-treatmentpre-methacholineimages (a).LACsshowlessmethacholine-inducedshifttotheleft atvisit
4 comparedwithvisit 2 (b), indicating the developmentof less air trappinginresponsetomethacholine (i.e. lessregional airwayhyper-
responsiveness) after treatment with HFA-BDPcomparedwith baseline.RV pre-treatment (F) and RV post-treatment (F).HU=-
Houns¢eldunit.Reproducedwiththe permission of J.G.Goldin and Mosby,Inc. (94).
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¢t (108); new in£ammatory agents are needed.
Traditional treatment for IPF consists of low-dose cor-
ticosteroids (e.g. prednisone) in combination with other
immunosuppressive agents (e.g. azathioprine or cyclo-
phosphamide), such that both in£ammation and immune
cell response would be controlled (30,40,109,110). As the
number of prospective studies on the treatment of IPF is
limited, de¢nitive evidence on the e⁄cacyof corticoster-
oids and immunosuppressive agents in improving survival
and quality of life is lacking (111,112). Responders to corti-
costeroid therapy seem to havebetter survival, although
it has not been established whether this is purely an ef-
fect of treatment.Greater likelihood of response to cor-
ticosteroid therapy has been correlated with shorter
illness duration, younger age, lesser disease severity and
histological features (34,40). A recent preliminary study
of interferon gamma-1b and low-dose prednisolone
showed favourable results in a small group of patients
with prednisolone-nonresponsive idiopathic pulmonary
¢brosis (113), but these encouraging ¢ndings need to be
con¢rmedby larger controlled clinical trials.
Intensive and adequate therapyof sarcoidosiswith sys-
temic corticosteroids, such as prednisone, improves the
functional derangement (114). However, a reduction in
dose or termination of therapy is often followed by clin-
ical relapse, requiring dosage adjustment and longer
duration of treatment (115,116). Delivery of disease-mod-
ulating drugs in sarcoidosis by the inhaled route is an at-
tractive option (117). Indeed, inhaled steroids have been
shown to be e¡ective in some instances.Clinical trials in
small numbers of patients with sarcoidosis treated with
budesonide have demonstrated a general improvement
of chest radiograph ¢ndings, an increase in inspiratory
vital capacity and a decrease in theT-lymphocyte count
in BAL £uid (118^120).The data suggest that inhaled bu-
desonidemay be an e¡ective and safe alternative to oral
steroids in the maintenance treatment of patients with
pulmonary sarcoidosis, especially in the early stage of
the disease (118,119).
Gupta (121) reported that satisfactory results were
obtainedwhenbudesonidewasused in combinationwith
oral steroids or non-steroidal anti-in£ammatory agents.
Similar observations have beenmade suggesting that se-
quential oral and inhaled therapy with corticosteroids,
rather than long-term oral corticosteroid therapy alone,
may be an alternative treatment regimen for stage II sar-
coidosis patients (122). Alberts et al. (123) have demon-
strated a positive e¡ect of inhaled budesonide on
symptoms and inspiratory VC in patients with newly di-
agnosed pulmonary sarcoidosis, suggesting that applica-
tion of local corticosteroids for the treatment of this
diseasemayreduce deterioration andpostpone theneed
for oral corticosteroids. However, contradictory data
obtained in an earlier study by Milman et al. (124) sug-
gested that inhaled budesonide has no e¡ect on sarcoi-dosis or on the biochemical markers of the disease
activity. It was speculated that this lack of e¡ect was
due to the poor (15%) deposition of inhaled budesonide
in the alveolar region, themajor site of the in£ammatory
process in the lungs. Similarly, du Bois et al. (117) have re-
cently demonstrated no objective bene¢t of inhaled £u-
ticasone propionate in pulmonary sarcoidosis,
suggesting that more e¡ective means of drug delivery
need to be developed.
A variety of therapies including azathioprine, cyclos-
porine, methotrexate and corticosteroids have been
used in the treatment of OB. Methotrexate (125), rapa-
mycin and le£unomide (126)mayprevent the progression
ofOB ando¡er a potentiallypromising therapeutic alter-
native in the treatment ofOB in lung transplantpatients.
Soghikian et al. (127) demonstrated that ganciclovir used
as a prophylaxis for cytomegalovirus infectionwas found
to delay the onset of this disease.
Despite the decrease in prevalence, mortality rate
and disease progression using immunosuppressive drug
therapy,OB still remains themost common complication
encountered after heart-lung transplantation.Moreover,
systemic side e¡ects are an important limitation of cur-
rent immunosuppressive therapy. In lymphocytic
bronchiolitis the airway represents an important target
for acute rejection, recognized histologically by lympho-
cytic in¢ltrates in the bronchiolar and bronchial epithe-
lium. Systemic corticosteroids have been shown to
reduce the number of lymphocytes identi¢ed in trans-
bronchial lung biopsy specimens following treatment for
acute rejection (128). However, the potential bene¢ts of
local (inhaled) drugs, such as ICS, to control in£amma-
toryeventswithin the airway and to avoid systemic com-
plications following lung transplantation have not been
well explored.Data from a small preliminary study have
shown a reduction in the frequency of acute lung rejec-
tion episodes andprevention of deterioration of pulmon-
ary function due to OB by inhaled budesonide,
supporting a bene¢cial use of ICS in the treatmentof this
disease (129). A more recent double-blind, placebo-con-
trolled, randomized trial in one patient has demon-
strated that high-dose £uticasone propionate is
e⁄cacious in the treatment of OB, as shown by an in-
crease in FEV1 (130).
It will be interesting to see if newer agents and those
agents being developed as reformulations of CFC-con-
taining aerosols meet this need for site-speci¢c delivery
of drugs to the smaller airways.
CONCLUSION
There is accumulating evidence that small airways
pathology contributes to a number of common lung dis-
eases.Changes in small airways function have been di⁄-
cult to measure, owing to the lack of speci¢city,
SMALL AIRWAYS INLUNGDISEASE 77sensitivity and consistency of pulmonary function tests.
This has resulted in the role of small airway obstruction
being largely under-estimated.
A combination of studies using biomarkers of in£am-
mation andnovel imaging techniques is beginning to pro-
vide a better understanding of the pathophysiology of
small airways obstruction in asthma, COPD, interstitial
lung diseases and OB. Identi¢cation of small airway dys-
function in these pulmonary disorders has raised the
need for the development of better methods of delivery
of anti-in£ammatory therapies to the peripheral air-
ways. Ongoing studies may help answer some of the
questions raised in this review.
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